StocksFundsScreenerSectorsWatchlists
RFL

RFL - Rafael Holdings Inc Stock Price, Fair Value and News

1.71USD0.00 (0.00%)Delayed

Market Summary

RFL
USD1.710.00
Delayed
0.00%

RFL Stock Price

View Fullscreen

RFL RSI Chart

RFL Valuation

Market Cap

40.4M

Price/Earnings (Trailing)

0.02

Price/Sales (Trailing)

12.36

EV/EBITDA

14.06

Price/Free Cashflow

-5.83

RFL Price/Sales (Trailing)

RFL Profitability

EBT Margin

69.97%

Return on Equity

2.4K%

Return on Assets

2.4K%

Free Cashflow Yield

-17.16%

RFL Fundamentals

RFL Revenue

Revenue (TTM)

3.3M

Rev. Growth (Yr)

123.22%

Rev. Growth (Qtr)

22.55%

RFL Earnings

Earnings (TTM)

2.5B

Earnings Growth (Yr)

286.06%

Earnings Growth (Qtr)

266.22%

Breaking Down RFL Revenue

Last 7 days

-2.8%

Last 30 days

-0.6%

Last 90 days

-4.5%

Trailing 12 Months

-17.8%

How does RFL drawdown profile look like?

RFL Financial Health

Current Ratio

23.01

RFL Investor Care

Shares Dilution (1Y)

2.10%

Diluted EPS (TTM)

0.09

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240000
20232.5M03.3M0
2022682.0K562.0K201.0K1.7M
20219.1M8.0M1.7M802.0K
20205.2M5.1M10.4M10.3M
20194.4M4.7M4.9M5.0M
20185.2M5.0M4.7M4.4M
20175.6M5.6M5.6M5.6M
2016005.6M0

Tracking the Latest Insider Buys and Sells of Rafael Holdings Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 04, 2024
jonas howard s
acquired
-
-
348,259
executive chairman
Apr 04, 2024
jonas howard s
sold
-
-
-348,259
executive chairman
Mar 21, 2024
conkling william
sold (taxes)
26,381
1.705
15,473
chief executive officer
Mar 21, 2024
polinsky david
sold (taxes)
-3,921
1.705
-2,300
chief financial officer
Jan 30, 2024
jonas howard s
acquired
-
-
348,259
executive chairman
Jan 30, 2024
jonas howard s
sold
-
-
-348,259
executive chairman
Jan 05, 2024
weiss michael j
acquired
50,055
1.81
27,655
-
Jan 05, 2024
mccamish mark anthony
acquired
50,055
1.81
27,655
-
Jan 05, 2024
greenberg stephen m
acquired
50,055
1.81
27,655
-
Dec 21, 2023
polinsky david
sold (taxes)
-15,610
1.82
-8,577
chief financial officer

1–10 of 50

Which funds bought or sold RFL recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 25, 2024
SIMPLEX TRADING, LLC
reduced
-17.9
-1,000
5,000
-%
Apr 24, 2024
Newbridge Financial Services Group, Inc.
unchanged
-
-165
2,580
-%
Apr 19, 2024
Cutler Group LLC / CA
unchanged
-
-1,000
9,000
-%
Apr 15, 2024
PFS Partners, LLC
unchanged
-
-160
2,494
-%
Apr 11, 2024
OPTIMUM INVESTMENT ADVISORS
unchanged
-
-440
6,880
-%
Apr 05, 2024
CWM, LLC
reduced
-97.91
-1,000
-
-%
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
unchanged
-
-140
3,660
-%
Mar 11, 2024
VANGUARD GROUP INC
added
2.03
-18,529
1,051,600
-%
Feb 16, 2024
HARBOUR INVESTMENTS, INC.
unchanged
-
-3.00
92.00
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
unchanged
-
-2,000
54,000
-%

1–10 of 45

Are Funds Buying or Selling RFL?

Are funds buying RFL calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own RFL
No. of Funds

Unveiling Rafael Holdings Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Aug 03, 2023
jonas howard s
5.5%
1,341,002
SC 13D/A
Feb 28, 2023
jonas howard s
4.2%
1,053,847
SC 13D/A
Feb 14, 2023
park west asset management llc
0%
0
SC 13G/A
Jul 18, 2022
i9 plus, llc
16.7%
3,338,367
SC 13D
Feb 14, 2022
park west asset management llc
6.5%
1,285,714
SC 13G/A
Feb 08, 2022
dimensional fund advisors lp
3.1%
609,939
SC 13G/A
Feb 12, 2021
dimensional fund advisors lp
5.2%
783,445
SC 13G/A
Feb 12, 2020
dimensional fund advisors lp
5.57%
834,792
SC 13G/A

Recent SEC filings of Rafael Holdings Inc

View All Filings
Date Filed Form Type Document
Apr 08, 2024
4
Insider Trading
Mar 25, 2024
4
Insider Trading
Mar 25, 2024
4
Insider Trading
Mar 14, 2024
8-K
Current Report
Mar 14, 2024
10-Q
Quarterly Report
Mar 13, 2024
8-K
Current Report
Feb 01, 2024
4
Insider Trading
Jan 18, 2024
4
Insider Trading

Peers (Alternatives to Rafael Holdings Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
37.6B
2.5B
-3.72% 20.05%
127.69
14.87
12.27% -19.89%
26.7B
31.9B
-9.86% 14.64%
27.06
0.84
3.64% -29.92%
10.2B
1.9B
-13.30% 2.63%
-64.57
5.25
-0.66% -56.44%
MID-CAP
8.7B
20.8B
-5.82% 34.05%
38.43
0.42
-0.49% -65.56%
3.4B
404.1M
1.97% 44.42%
42.07
8.46
55.15% 19.63%
2.7B
821.4M
-12.93% 35.35%
14.47
3.26
18.22% 157.58%
2.2B
9.5B
-5.63% 2.21%
-62.48
0.23
-6.06% -118.02%
SMALL-CAP
1.6B
4.3B
1.10% -11.15%
-174.44
0.37
-6.90% -158.11%
222.4M
50.5M
-24.01% -25.65%
56.05
4.4
34.51% -98.94%
109.5M
44.5M
-10.67% 46.99%
49.12
2.46
-24.76% -93.06%
68.9M
44.7M
40.12% 63.47%
8.86
1.54
13.76% 5.95%
52.6M
145.1M
- -49.09%
-1
0.36
-5.22% 2.46%

Rafael Holdings Inc News

Latest updates
Defense World10 Apr 202407:00 am
The Motley Fool2 years ago

Rafael Holdings Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue22.5%6,008,0004,902,5003,797,0002,691,5001,586,00081,000--120,000442,000120,000120,0001,053,0006,745,0001,224,0001,236,0001,210,0001,416,0001,377,0001,017,0001,107,000
  S&GA Expenses25.5%2,561,0002,040,0001,395,0002,085,0003,109,0003,048,0003,336,000-1,680,00012,274,0008,659,0003,006,0002,767,0002,592,0002,775,0002,081,0002,221,0002,041,0003,593,0002,059,0001,716,0001,453,000
  R&D Expenses25.2%612,000489,0001,266,0002,225,0002,081,0001,841,0001,413,0003,335,0002,153,0001,562,0001,262,0001,568,000515,0001,064,000634,000448,000245,00078,000300,000276,000373,000
EBITDA Margin133.8%0.73-2.15-2.66-7.32-10.08-696-261-212-187-13.46-1.58-1.31-0.49-0.49-1.17-0.97-0.75-0.55-0.34-0.19-0.37
Interest Expenses-------13,0001,000-13,0007,0003,000-1,000--1,000-33,000-64,000-178,000-221,000767,000101,000
Income Taxes-100.0%-6,0004,0005,0005,000-2,0004,000-5,0004,0004,0005,0005,0008,00012,0004,0002,000-7,00017,000-31,000
Earnings Before Taxes272.7%6,110,000-3,538,0001,463,000-3,247,000-5,202,000-4,645,000-4,981,000-2,053,000-128,293,000-10,833,000-2,742,000-8,329,000-1,522,000-1,664,000-2,288,000-1,316,000-1,648,000-2,409,000-1,154,000-684,000-696,000
EBT Margin132.1%0.70-2.18-2.69-7.35-10.13-696-260-211-187-13.50-1.77-1.51-0.66-0.66-1.51-1.25-1.17-1.01-0.83-0.77-0.79
Net Income266.2%6,047,000-3,638,0007,142,116,500-3,250,0001,592,0004,717,958,500-5,548,000-2,057,000-128,868,000-10,743,000-2,650,000-8,237,000-1,431,000-5,743,000-2,159,000-1,253,000-1,598,000-2,186,000-1,005,000-1,021,000-481,000
Net Income Margin0.3%7717687685137576,261-261-211-187-13.29-2.25-1.92-1.03-1.03-1.41-1.15-1.16-0.95-0.67-0.60-0.50
Free Cashflow-18.6%-2,529,000-2,133,000-1,449,000-5,545,000-2,581,000-1,903,000-10,365,000-7,310,000-6,503,000-6,950,000-3,125,000-2,934,000-2,798,000-1,734,000-1,110,000-1,099,000-1,257,000-629,000-1,945,000-207,000-750,000
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets11.1%10696.0099.0096.0099.00103118113123130154146146135136137139140142143144
  Current Assets-3.1%75.0077.0083.0085.0090.0095.0010863.0072.0079.0015.006.007.008.0010.009.0010.0012.0013.0015.0016.00
    Cash Equivalents-45.9%7.0013.0021.0015.0010.0023.0027.0029.0070.0072.0013.005.006.007.006.008.0010.0011.0012.0013.0015.00
  Net PPE23.5%2.002.002.002.002.002.002.0042.0043.0043.002.0044.0044.0044.0044.0048.0048.0049.0049.0049.0049.00
  Goodwill-4.00--------------------
Liabilities293.4%4.001.002.001.002.003.0021.0018.0023.0017.0017.005.0011.005.006.002.001.001.0017.0017.0016.00
  Current Liabilities249.4%3.001.002.001.002.003.0021.0018.0023.0017.0017.005.0011.005.006.001.001.001.001.001.001.00
Shareholder's Equity11.0%10595.0010099.0097.0010097.0095.00100113137141135129131136138139125127128
  Retained Earnings3.5%-164-170-167-168-167-163-165-160-155-152-40.80-28.42-25.87-17.70-16.25-10.85-8.69-7.44-5.84-3.65-2.65
  Additional Paid-In Capital0.3%266265264264263263262255254265159151143129129129129129113117117
Shares Outstanding0.0%24.0024.0023.0023.0023.0023.0020.0020.0020.0019.0017.0016.0016.0016.0016.0016.0016.0016.0013.0013.0013.00
Minority Interest27.3%-2.68-3.69-3.66-3.64-3.57-3.41-3.31-3.24-3.22-2.9714.0014.0015.0014.0014.0014.0014.0014.0014.009.009.00
Float-----70.00---70.00---330---184---96.00
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-18.6%-2,529-2,133-1,448-1,314-5,544-2,580-1,902-10,366-7,337-6,474-6,981-3,093-2,874-2,653-1,691-1,075-964-936-594-1,639-175
  Share Based Compensation10.2%715649540591-1231,1801,1721,008-10,9487,8515,61030450521424213510994.00---
Cashflow From Investing58.9%-2,791-6,7867,4077,387-7,55713,974-6,377-30,482-33.00-26,904531-282-12,0583,638-543-35.00-135-321-35.00-306-25,738
Cashflow From Financing-215.5%-932807-35.00-26.00-151-15,0065,997-1.00-41.0097,90914,5281,96113,76643.00-20.00--35.0027.0030,709
  Buy Backs12.7%89.0079.00-------------------

RFL Income Statement

2024-01-31
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended6 Months Ended
Jan. 31, 2024
Jan. 31, 2023
Jan. 31, 2024
Jan. 31, 2023
REVENUE    
Total revenue$ 68$ 70$ 136$ 140
COSTS AND EXPENSES    
General and administrative2,5612,0854,6015,194
Research and development6122,2251,1014,306
Depreciation and amortization38195541
Loss from operations(3,143)(4,259)(5,621)(9,401)
Interest income6935621,275770
Impairment of investments - Other Pharmaceuticals(67)(223)
Loss on initial investment in Day Three upon acquisition(1,633)(1,633)
Realized gain on available-for-sale securities399139576154
Realized loss on investment in equity securities(46)
Realized gain on investments - Cyclo Therapeutics Inc.424
Unrealized gain on investments - Cyclo Therapeutics Inc.9,7187,594
Unrealized gain (loss) on investments - Hedge Funds51378(115)251
Other Income25118
Income (loss) from continuing operations before income taxes6,110(3,247)2,572(8,449)
Provision for income taxes(5)(6)(10)
Equity in loss of Day Three(206)(422)
Consolidated net income (loss) from continuing operations5,904(3,252)2,144(8,459)
Discontinued Operations (Note 3)    
Loss from discontinued operations related to 520 Property(157)(241)
Gain on disposal of 520 Property6,784
Income (loss) from discontinued operations(157)6,543
Consolidated net income (loss)5,904(3,409)2,144(1,916)
Net loss attributable to noncontrolling interests(143)(159)(265)(258)
Net income (loss) attributable to Rafael Holdings, Inc.6,047(3,250)2,409(1,658)
Unrealized gain on available-for-sale securities58268265371
Foreign currency translation adjustment46(16)(30)(26)
Comprehensive income (loss)6,008(3,157)2,379(1,571)
Comprehensive loss attributable to noncontrolling interests(145)(156)(264)(255)
Comprehensive income (loss) attributable to Rafael Holdings, Inc.$ 6,153$ (3,001)$ 2,643$ (1,316)
Basic:    
Continuing operations (in Dollars per share)$ 0.26$ (0.13)$ 0.1$ (0.36)
Discontinued operations (in Dollars per share)(0.01)0.28
Total basic income (loss) per share (in Dollars per share)0.26(0.14)0.1(0.08)
Diluted:    
Continuing operations (in Dollars per share)0.25(0.13)0.1(0.36)
Discontinued operations (in Dollars per share)(0.01)0.28
Total diluted income (loss) per share (in Dollars per share)$ 0.25$ (0.14)$ 0.1$ (0.08)
Weighted average number of shares used in calculation of income (loss) per share    
Basic (in Shares)23,642,42123,155,01823,643,66023,085,612
Diluted (in Shares)24,402,06923,155,01824,403,30823,085,612
Rental – Third Party    
REVENUE    
Total revenue$ 41$ 43$ 82$ 86
Rental – Related Party    
REVENUE    
Total revenue$ 27$ 27$ 54$ 54

RFL Balance Sheet

2024-01-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Jan. 31, 2024
Jul. 31, 2023
CURRENT ASSETS  
Cash and cash equivalents$ 7,136$ 21,498
Available-for-sale securities64,58757,714
Interest receivable560387
Accounts receivable, net of allowance for doubtful accounts of $245 at January 31, 2024 and July 31, 2023379213
Prepaid expenses and other current assets487914
Investment in equity securities294
Total current assets75,07382,941
Property and equipment, net2,0641,695
Goodwill3,571
Intangible assets1,888 
In-process research and development1,5751,575
Other assets429
TOTAL ASSETS106,14998,829
CURRENT LIABILITIES  
Accounts payable509333
Accrued expenses845763
Other current liabilities1401,023
Installment note payable1,700 
Total current liabilities3,2632,145
Deferred income tax liabilities, net545 
Other liabilities8755
TOTAL LIABILITIES3,8952,200
COMMITMENTS AND CONTINGENCIES
EQUITY  
Additional paid-in capital266,159264,010
Accumulated deficit(164,924)(167,333)
Treasury stock, at cost; 101,487 and 0 Class B shares as of January 31, 2024 and July 31, 2023, respectively(168)
Accumulated other comprehensive loss related to unrealized loss on available-for-sale securities(88)(353)
Accumulated other comprehensive income related to foreign currency translation adjustment3,7143,725
Total equity104,939100,293
Noncontrolling interests(2,685)(3,664)
TOTAL EQUITY ATTRIBUTABLE TO RAFAEL HOLDINGS, INC.102,25496,629
TOTAL LIABILITIES AND EQUITY106,14998,829
Class A Common Stock  
EQUITY  
Common stock value88
Class B Common Stock  
EQUITY  
Common stock value238236
Other Pharmaceuticals  
CURRENT ASSETS  
Investments65
Hedge Funds  
CURRENT ASSETS  
Investments2,3694,984
Day Three  
CURRENT ASSETS  
Investments 2,797
Cyclo Therapeutics Inc.  
CURRENT ASSETS  
Investments19,5674,763
Related Party  
CURRENT ASSETS  
Convertible note receivable, related party1,9241,921
CURRENT LIABILITIES  
Due to related parties$ 69$ 26
RFL
Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), that is in Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.
 WEBSITErafaelholdings.com
 INDUSTRYReal Estate Services
 EMPLOYEES22

Rafael Holdings Inc Frequently Asked Questions


What is the ticker symbol for Rafael Holdings Inc? What does RFL stand for in stocks?

RFL is the stock ticker symbol of Rafael Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Rafael Holdings Inc (RFL)?

As of Fri Apr 26 2024, market cap of Rafael Holdings Inc is 40.43 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RFL stock?

You can check RFL's fair value in chart for subscribers.

What is the fair value of RFL stock?

You can check RFL's fair value in chart for subscribers. The fair value of Rafael Holdings Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Rafael Holdings Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RFL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Rafael Holdings Inc a good stock to buy?

The fair value guage provides a quick view whether RFL is over valued or under valued. Whether Rafael Holdings Inc is cheap or expensive depends on the assumptions which impact Rafael Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RFL.

What is Rafael Holdings Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, RFL's PE ratio (Price to Earnings) is 0.02 and Price to Sales (PS) ratio is 12.36. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RFL PE ratio will change depending on the future growth rate expectations of investors.